ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Deal DateR&D LicensorClient LicenseeDeal SubjectDeal TypesDeal Size ($M)Stage at SigningDiseasesIndicationsTechnologiesSub TechnologiesCompound NameMechanism of ActionMolecular TargetDeal SourceDeal LinkUpfront Cash ($M)Upfront Equity ($M)Dev / Reg Milestones ($M)Add'l Dev Milestones ($M)Total Precommercial Payments ($M)Sales Milestones ($M)Maximum Royalty (%)Financial Term Explanations
2
04/2020Adaptive BiotechnologiesAmgenFully human neutralizing antibodies targeting SARS-CoV-2 to treat COVID-19License, ResearchDiscoveryInfectious-ViralCoronavirusMonoclonalsHuman AbsCOVID-19 antibody therapyfully human anti-SARS-CoV-2 neutralizing antibodies2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
3
04/2020BARDAGrifolsPlasma collection and evaluation of anti-SARS-CoV-2 hyperimmune globulin therapy to treat COVID-19ResearchInfectious-ViralCoronavirusPRLink
4
04/2020Emergent BioSolutionsDepartment of Health and Human Services, BARDAFunding to support development of COVID-HIG plasma-derived therapy for COVID-19 infectionDevelopment 14.50 Lead MoleculeInfectious-ViralCoronavirusMonoclonalsCOVID-HIG, COVID-19 human plasma-derived therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
5
04/2020Integrated Translational Research Institute of Virginia, University of VirginiaDiffusion PharmaceuticalsEvaluation of small molecule Trans Sodium Crocetinate in ARDS-related COVID-19 patientsResearchPreclinicalInfectious-Viral, RespiratoryCoronavirus, Other RespiratorySyntheticsSmall MoleculePRLink
6
04/2020Mass General HospitalHaloVaxSponsored research agreement to accelerate development of self-assembling vaccine for COVID-19ResearchPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 self-assembling vaccine platformProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
7
04/2020Mount SinaiBiomericaTechnology related to serological test for COVID-19 to scale-up commercial manufacturingLicenseDiagnosticInfectious-ViralCoronavirusDiagnosticsPRLink
8
04/2020NeurimmuneEthrisInhaled mRNA-based neutralizing anti-SARS-CoV-2 antibody therapy to treat COVID-19Co-Development, LicenseLead MoleculeInfectious-ViralCoronavirusDrug Delivery, MonoclonalsCOVID-19 antibody therapymRNA-encoded neutralizing anti-SARS-CoV-2 antibodies2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
9
04/2020NovellusCitius PharmaceuticalsStem cell therapy for acute respiratory distress syndrome associated with COVID-19License, OptionInfectious-Viral, RespiratoryCoronavirus, Other RespiratoryCell Therapy - Stem Cells/FactorsPRLink
10
04/2020University of WisconsinBharat Biotech, FlugenCoroFlu COVID-19 vaccine based on intranasal M2SR flu vaccineDevelopmentPreclinicalInfectious-ViralCoronavirusVaccinesCoroFlu, COVID-19 vaccineLive Attenuated2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
11
03/20203D MedicinesTodos MedicalCoronavirus and influenza A/B testing kit distribution in the US and IsraelDistributionDiagnosticInfectious-ViralCoronavirus, InfluenzaDiagnosticsPRLink
12
03/2020AbCelleraLillyAntibody products for treatment and prevention of COVID-19Co-Development, LicenseDiscoveryInfectious-ViralCoronavirusMonoclonalsCOVID-19 antibody therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
13
03/2020Beth IsraelJanssenPreclinical testing of vaccine prospects to identify COVID-19 vaccine candidate for clinical trialsResearchPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineReplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
14
03/2020BioNTechPfizerBNT162 mRNA-based vaccine to prevent COVID-19 infection ex-ChinaCo-Development, Distribution, Letter of Intent, LicensePreclinicalInfectious-ViralCoronavirusVaccinesBNT162mRNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
15
03/2020BioNTechFosun PharmaceuticalBNT162 mRNA-based vaccine to prevent COVID-19 infection in ChinaEquity, License, Supply 185.00 PreclinicalInfectious-ViralCoronavirusVaccinesBNT162mRNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink 50.00 USD 50 million (EUR 44 million) for 1,580,777 ordinary shares in BioNTech | 135M (EUR 120M) in upfront and potential future investment and milestone payments
16
03/2020BioSig TechnologiesNeuroClear TechnologiesVicromax broad-spectrum anti-viral agent for COVID-19 to be developed by new subsidiary ViralClearLicensePreclinicalInfectious-ViralCoronavirusSyntheticsSmall MoleculeVicromax2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
17
03/2020CanSinoBIOBeijing Institute of BiotechnologyAd5-nCoV recombinant coronavirus vaccine candidateCo-DevelopmentPreclinicalInfectious-ViralCoronavirusVaccinesAd5-nCoVNonreplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
18
03/2020Charite UniversityPluristem TherapeuticsEvaluation of PLX cell product candidates to treat complications associated with COVID-19ResearchPreclinicalInfectious-ViralCoronavirusCell Therapy - Stem Cells/FactorsPLX cells2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
19
03/2020Clover BiopharmaceuticalsDynavax TechnologiesEvaluation of COVID-19 S-Trimer coronavirus vaccine candidate with CpG 1018 adjuvantResearchPreclinicalInfectious-ViralCoronavirusAdjuvant, VaccinesCOVID-19 S-TrimerProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
20
03/2020Cystron BiotechAkers BiosciencesAcquisition for cash and sharesAcquisition 1.00 Lead MoleculeInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)SEC FullLink
21
03/2020Duke-NUS Medical SchoolArcturus TherapeuticsSTARR technology to develop coronavirus vaccineResearchPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineRNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
22
03/2020Dynavax TechnologiesCEPI, University of QueenslandCpG 1018 adjuvant to support development of vaccine for coronavirusResearchReagentInfectious-ViralCoronavirusAdjuvantPRLink
23
03/2020Emergent BioSolutionsNovavaxManufacture of NanoFlu recombinant quadrivalent seasonal influenza vaccine candidateSupplyPhase IIIInfectious-ViralInfluenzaVaccinesPRLink
24
03/2020Emergent BioSolutionsVaxartCDMO services to manufacture oral recombinant vaccine candidate for COVID-19Development, SupplyPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineNonreplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
25
03/2020Emergent BioSolutionsNovavaxManufacture of COVID-19 experimental vaccine candidateDevelopment, SupplyPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
26
03/2020EVQLVImmunoPrecise Antibodies, Talem TherapeuticsComputational antibody design to generate leads and accelerate COVID-19 antibody discoveryLicense, ResearchDiscoveryInfectious-ViralCoronavirusBioinformatics, MonoclonalsCOVID-19 antibody therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
27
03/2020Generex BiotechnologySinotek-Advocates International, Beijing ZhonghuaCOVID-19 vaccine dev via Ii-Key peptide vaccine platform in Greater ChinaDevelopment, License, Supply 6.00 Lead MoleculeInfectious-ViralCoronavirusPeptides, VaccinesCOVID-19 vaccinePeptide2019-nCoV (SARS-CoV-2) (COVID-19)SEC FullLink 5.00 6.00 $1M initial dev cost pre-payment
28
03/2020IDbyDNAIlluminaExplify Platform to detect COVID-19 and other infectious diseasesCo-MarketDiagnosticInfectious-ViralBroad Focus Infectious-Viral, CoronavirusDiagnostics, GenomicsDNA Probes, Gene SequencingPRLink
29
03/2020Inovio PharmaceuticalsBill & Melinda Gates FoundationCellectra 3PSP device for intradermal delivery of INO-4800 DNA vaccine for COVID-19Research 5.00 DeviceInfectious-ViralCoronavirusDevice, VaccinesINO-4800DNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink 5.00
30
03/2020Institute of Materia MedicaCyclicaMatchMaker deep learning engine to identify compounds for repurposing to treat COVID-19ResearchDiscoveryInfectious-ViralCoronavirusScreeningPRLink
31
03/2020Institute of Microbiology of the Chinese Academy of SciencesShanghai Junshi BiosciencesNeutralizing antibody-based therapies for COVID-19License, ResearchPreclinicalInfectious-ViralCoronavirusMonoclonalsCOVID-19 antibody therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
32
03/2020Kleo PharmaceuticalsGreen Cross LabCellCOVID-19-targeting allogeneic NK cell combination therapyAsset Purchase, ResearchDiscoveryInfectious-ViralCoronavirusCell Therapy - Stem Cells/Factors, MonoclonalsBispecificCOVID-19 antibody/cell therapyAntibody Recruiting Molecule (ARM)/Natural Killer (NK) Cell Therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
33
03/2020MabpharmSorrento TherapeuticsACE-MAB bi-specific fusion protein for COVID-19 in North America and EuropeLicensePreclinicalInfectious-ViralCoronavirusMonoclonalsBispecificACE-MABACE2 enzyme/fully human antibody2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
34
03/2020Mass General HospitalVoltron Therapeutics, Hoth TherapeuticsVaxCelerate self-assembling vaccine platform against COVID-19LicensePreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 self-assembling vaccine platformProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
35
03/2020Moderna TherapeuticsDepartment of Health and Human Services, BARDADevelopment support for mRNA-1273 vaccine to treat COVID-19DevelopmentPreclinicalInfectious-ViralCoronavirusVaccinesmRNA-1273mRNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
36
03/2020Premas BiotechAkers BiosciencesD-Crypt platform for COVID-19 vaccineLicenseLead MoleculeInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink 1.00 $1 million upfront payment for acquisition of Cystron | 622,756 shares of common stock for acquisition of Cystron
37
03/2020Premas BiotechAkers Biosciences, Cystron BiotechD-Crypt platform for COVID-19 vaccineLicense 2.00 Lead MoleculeInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)SEC FullLink 0.25 1.75 2.00 royalty-free
38
03/2020Q2 SolutionsUniversity of Texas Medical BranchLaboratory services to accelerate development of COVID-19 vaccinesServicesDiagnosticInfectious-ViralCoronavirusDiagnosticsPRLink
39
03/2020Relief TherapeuticsNeuroRxAviptadil to treat COVID-19-induced acute respiratory distress syndromeLicensePreclinicalInfectious-Viral, RespiratoryCoronavirus, Other RespiratoryPeptidesaviptadil, RLF-100vasoactive intestinal peptide receptor agonists2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
40
03/2020Sartorius Stedim BiotechInstitute of Bioengineering, CanSinoBIOBIOSTAT STR single-use bioreactor system to accelerate development of coronavirus vaccineDevelopment, SupplyReagentInfectious-ViralCoronavirusRecombinant DNA, VaccinesAd5-nCoVNonreplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
41
03/2020Shanghai Liangrun Biomedicine Technology, GibraltarTodos MedicalPoint-of-care rapid antibody testing kit for Coronavirus in the US and IsraelDistributionDiagnosticInfectious-ViralCoronavirusDiagnosticsPRLink
42
03/2020SIGA TechnologiesTurnstone BiologicsTPOXX (tecovirimat) to support SKV vaccinia oncolytic immunotherapy platformSupplyPreclinicalInfectious-ViralSyntheticsSmall MoleculeTPOXX, tecovirimatPRLink
43
03/2020SmartPharmSorrento TherapeuticsGene-encoded antibody vaccine for COVID-19Development, LicenseLead Molecule, FormulationInfectious-ViralCoronavirusDrug Delivery, VaccinesCOVID-19 gene-encoded antibody vaccineGene-Encoded Antibody Vaccine2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
44
03/2020Todos MedicalEmerald OrganicFormation of Corona Diagnostics joint venture to supply COVID-19 screening and diagnostic testingJoint VentureDiagnosticInfectious-ViralCoronavirusDiagnosticsPRLink
45
03/2020Torque TherapeuticsCogen Immune MedicinesMerger of two Flagship Pioneering companies to form Repertoire Immune MedicinesAcquisitionAutoimmune/Inflammatory, Cancer, Infectious-ViralPRLink
46
03/2020Translate BioSanofi, Sanofi PasteurmRNA vaccine candidate against COVID-19License, ResearchDiscoveryInfectious-ViralCoronavirusVaccinesCOVID-19 vaccinemRNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
47
03/2020Twist BioscienceVanderbilt UniversitySynthetic genes and antibodies for the development of therapies for COVID-19Research, SupplyDiscovery, ReagentInfectious-ViralCoronavirusMonoclonals, ScreeningCOVID-19 antibody therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
48
03/2020University of GeorgiaEpiVaxBioinformatics to develop a vaccine against COVID-19ResearchDiscoveryInfectious-ViralCoronavirusBioinformatics, VaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
49
03/2020University of MiamiHeat BiologicsImmune activating gp96 vaccine platform to protect against COVID-19 coronavirusResearchPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
50
03/2020University of MiamiHeat BiologicsRapid point-of-care diagnostic for COVID-19ResearchDiagnosticInfectious-ViralCoronavirusDiagnosticsPRLink
51
03/2020University of Texas Medical BranchSorrento TherapeuticsPreclinical testing of Sorrento’s COVID-19 therapeutic product candidatesResearchPreclinicalInfectious-ViralCoronavirusCell Therapy - Stem Cells/Factors, Monoclonals, Recombinant DNACOVID-19 therapyundisclosed2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
52
03/2020University of Texas Medical BranchMoleculinWP1122 prodrug of 2-DG (2-deoxy-D-glucose) for COVID-19ResearchPreclinicalInfectious-ViralCoronavirusSyntheticsSmall MoleculeWP1122metabolism/glycosylation inhibitor2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
53
03/2020Vir BiotechnologyBiogenMonoclonal to treat COVID-19Co-Development, Letter of Intent, SupplyLead MoleculeInfectious-ViralCoronavirusMonoclonalsCOVID-19 antibody therapyhuman anti-SARS-CoV-2 monoclonal antibodies2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
54
03/2020Voltron TherapeuticsHoth TherapeuticsFormation of HaloVax joint venture to begin preclinical development of SAV for COVID-19Joint VenturePreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 self-assembling vaccine platformProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
55
03/2020WPD PharmaceuticalsCNS PharmaceuticalsPreclinical antiviral candidates including WP1122 prodrug of 2-DG for coronavirusLicense 1.00 PreclinicalInfectious-ViralCoronavirusSyntheticsSmall MoleculeWP1122metabolism/glycosylation inhibitor2019-nCoV (SARS-CoV-2) (COVID-19)PRLink 0.23 0.78
56
03/2020XencorVir BiotechnologyXtend Fc technology to extend antibody drug half-life in treatments for COVID-19LicenseFormulationInfectious-ViralCoronavirusDrug Delivery, MonoclonalsSustained ReleaseCOVID-19 antibody therapyundisclosed2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
57
03/2020ZolovaxHeat BiologicsImmune activating gp96 vaccine platform to protect against COVID-19 coronavirusResearchPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
58
02/2020Clover BiopharmaceuticalsGlaxoSmithKlineEvaluation of COVID-19 S-Trimer coronavirus vaccine candidate with pandemic adjuvant systemResearchPreclinicalInfectious-ViralCoronavirusAdjuvant, VaccinesCOVID-19 S-TrimerProtein Subunit2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
59
02/2020HarvardGuangzhou InstituteCoronavirus research to develop therapies and improve diagnosticsResearchDiscoveryInfectious-ViralCoronavirusDiagnostics, Monoclonals, VaccinesCOVID-19 therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLinkHarvard and Guangzhou Institute will share $115M in research funding provided by China Evergrande Group
60
02/2020Johnson & Johnson, JanssenDepartment of Health and Human Services, BARDAExpanded vaccine collaboration to accelerate development of COVID-19 treatmentsDevelopmentPreclinicalInfectious-ViralCoronavirusVaccinesCOVID-19 vaccineNonreplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
61
02/2020Kansas State UniversityCocrystal PharmaBroad-spectrum antiviral compounds to treat Norovirus and Coronavirus infectionsLicenseLead MoleculeInfectious-ViralCoronavirusScreeningCOVID-19 therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
62
02/2020MedivirShijiazhuang Yuanmai BiotechnologyXerclear for herpes in ChinaLicensePhase IIIInfectious-ViralOther Infectious-ViralDrug Delivery, SyntheticsSmall Molecule, TopicalPRLink
63
02/2020Pinpoint SciencePathogen DetectionNanosensor diagnostic platform for pathogen detectionResearchDiagnosticInfectious-Bacterial, Infectious-ViralBroad Focus Infectious-Bacterial, Broad Focus Infectious-Viral, CoronavirusDevice, DiagnosticsPRLink
64
02/2020SanofiBARDARecombinant technology platform to expedite COVID-19 vaccine previously developed for SARSDevelopmentPreclinicalInfectious-ViralCoronavirusRecombinant DNA, VaccinesCOVID-19 vaccineDNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
65
02/2020Serum Institute of IndiaCodagenixRationally designed live-attenuated vaccine against coronavirus COVID-19Co-DevelopmentDiscoveryInfectious-ViralCoronavirusBioinformatics, VaccinesCDX-CoV, COVID-19 vaccineLive Attenuated2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
66
02/2020Sherlock BiosciencesCepheidSHERLOCK CRISPR-based technology to develop molecular diagnostics on GeneXpert SystemsResearchDiagnosticCancer, Infectious-ViralBroad Focus Cancer, Broad Focus Infectious-Viral, CoronavirusDiagnosticsPRLink
67
02/2020Southern Research InstituteTonix PharmaceuticalsTNX-1800 (horsepox virus vector) as vaccine for coronavirusCo-DevelopmentLead MoleculeInfectious-ViralCoronavirusVaccinesTNX-1800Live Modified2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
68
02/2020Tianjin UniversityBeroni GroupComputer-aided modification of nano-antibodies for detection and treatment of COVID-19ResearchDiscovery, DiagnosticInfectious-ViralCoronavirusBioinformatics, Diagnostics, MonoclonalsCOVID-19 antibody therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
69
02/2020WuXi PharmaTechVir BiotechnologyMonoclonal to treat COVID-19Co-Development, License, SupplyLead MoleculeInfectious-ViralCoronavirusMonoclonalsCOVID-19 antibody therapyhuman anti-SARS-CoV-2 monoclonal antibodies2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
70
01/2020CelularitySorrento TherapeuticsCYNK-001 NK cell therapy manufacture for coronavirusResearch, SupplyPreclinicalInfectious-ViralCoronavirusCell Therapy - Stem Cells/FactorsCYNK-001natural-killer (NK) cell therapy2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
71
01/2020GeoVax LabsBravoVaxMVA-VLP-based vaccine candidates against coronavirusCo-Development, Letter of Intent, ResearchDiscoveryInfectious-ViralCoronavirusVaccinesMVA-VLP-based vaccine, GV-MVA-VLPNonreplicating Viral Vector2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
72
01/2020Inovio PharmaceuticalsBeijing Advaccine BiotechnologyINO-4800 vaccine against coronavirus in ChinaLicensePreclinicalInfectious-ViralCoronavirusVaccinesINO-4800DNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
73
01/2020NIH, National Institute of Allergy and Infectious Diseases, Moderna TherapeuticsCEPIFunding to support development of Moderna/NIAID mRNA vaccine (mRNA-1273) against coronavirusResearchPreclinicalInfectious-ViralCoronavirusVaccinesmRNA-1273mRNA2019-nCoV (SARS-CoV-2) (COVID-19)PRLink
74
01/2020SAB BiotherapeuticsCSL LimitedDiversitAb platform to produce human immunoglobulin for autoimmune, infectious & idiopathic diseasesLicense, Option, ResearchDiscoveryAutoimmune/Inflammatory, Infectious-Bacterial, Infectious-ViralMonoclonalsPRLink
75
01/2020Scripps Research InstituteBill & Melinda Gates FoundationReFRAME drug screening for malaria, tuberculosis & COVID-19Development, Research 50.00 DiscoveryInfectious-Bacterial, Infectious-Miscellaneous, Infectious-ViralCoronavirus, Malaria, TuberculosisScreeningPRLink 50.00
76
12/2019CytoDynVyera PharmaceuticalsLeronlimab (PRO 140) for HIV in the USEquity, License, Supply 91.50 Phase IIIInfectious-ViralHuman Immunodeficiency Virus/HIVMonoclonalsHumanized Absleronlimab, PRO 140, PA-14, WHO 10751anti-CCR5 humanized IgG4 monoclonal antibody inhibitorCC chemokine receptor type 5 (CCR5) (CD195)SEC RedactedLink 0.50 4.00 91.50 $87M in agg milestones, per CytoDyn's 2019 10-K | 50% of gross profits, per CytoDyn's 2019 10-K
77
12/2019SanofiDepartment of Health and Human ServicesContract to produce adjuvanted recombinant vaccine to expand pandemic influenza preparednessDevelopment 226.00 Infectious-ViralInfluenzaAdjuvant, VaccinesPRLink
78
11/2019G-Tech BioEnochian BiopharmaUndisclosed preclinical HBV treatmentLicensePreclinicalInfectious-ViralHepatitis BPRLink
79
11/2019National Institute of Allergy and Infectious DiseasesGlaxoSmithKlineN6LS broadly neutralising antibody for HIV, to be developed by ViiV Healthcare joint ventureLicensePhase IInfectious-ViralHuman Immunodeficiency Virus/HIVMonoclonalsHuman AbsPRLink
80
10/2019Dicerna PharmaceuticalsRocheRG6346 (DCR-HBVS) for hepatitis BCo-Development, Co-Promotion, License, Option, Research 1,670.00 Phase I, DiscoveryInfectious-ViralHepatitis BOligonucleotidesRNAiSEC RedactedLink 200.00 1,670.00 up to mid-teen royalties; Dicerna has option to co-fund pivotal trials, for 20s-30s US royalties and US co-promotion rights, per Dicerna's 2019 10-K | $1.47B in agg milestones, per Dicerna's 2019 10-K
81
10/2019GlaxoSmithKlineBavarian NordicAcq. of RabAvert for prevention of rabies and Encepur for prevention of tick-borne encephalitisAsset PurchaseApprovedInfectious-ViralOther Infectious-ViralVaccinesPRLink 336.00 €301 million ($336 million) | €159 million ($177M) for existing inventory, €495 million ($550M) in milestone payments
82
10/2019Vaxess TechnologiesGC PharmaMIMIX smart release patch for delivery of influenza vaccineLicenseFormulationInfectious-ViralInfluenzaDrug DeliveryTransdermalPRLink
83
09/2019BioNTechBill & Melinda Gates Foundation$55M investment to develop preclinical vaccine and immunotherapy candidates for HIV and tuberculosisDevelopment, EquityPreclinicalInfectious-Bacterial, Infectious-ViralHuman Immunodeficiency Virus/HIV, TuberculosisPRLink 55.00 Total funding could reach $100M
84
09/2019NovartisAmplyx PharmaceuticalsMAU868 anti-BK virus mAb to treat and prevent BKV disease in transplant patientsLicensePhase IIInfectious-ViralOther Infectious-ViralMonoclonalsMAU868polyomavirus BK virus (BKV)PRLink
85
08/2019Emergent BioSolutionsDepartment of Health and Human Services, BARDA, NIHACAM2000 Vaccinia IGIV smallpox vaccine supply for strategic national stockpileSupply 2,000.00 Infectious-ViralOther Infectious-ViralAdjuvant, VaccinesSEC RedactedLink 2,000.00 $2B contract value
86
08/2019Ology BioservicesBlue Water VaccinesManufacture of universal influenza vaccineSupplyPreclinicalInfectious-ViralInfluenzaVaccinesPRLink
87
07/2019Aridis PharmaceuticalsSerum Institute of IndiaMabIgX platform for asset identification and selection, option to AR-301, AR-105, AR-101, AR-201Equity, License, Option 25.00 Phase III, PreclinicalInfectious-Bacterial, Infectious-ViralPneumonia, Respiratory Syncytial Virus/RSVMonoclonalsHuman AbsSEC RedactedLink 15.00 10.00 801K shares @ $12.47/sh (31% premium)
88
07/2019DurectGileadSABER technology for long-acting injectable HIV and HBV therapyLicense, Option 320.00 FormulationInfectious-ViralHepatitis B, Human Immunodeficiency Virus/HIVDrug DeliverySustained ReleaseSEC RedactedLink 25.00 75.00 150.00 250.00 70.00 Tiered single-digit royalties, per Durect's 6Q19 | $75M in development and regulatory milestones, per Durect's 6Q19 | Option to additional SABER-based products directed to HIV and HBV for an additional $150M per product in upfront, development, regulatory and sales based milestones, per Durect's 6Q19
89
07/2019KinetaNIH, National Institute of Allergy and Infectious Diseases$5.8M grant to evaluate LHF-535 as treatment for hemorrhagic arenavirusesResearch 5.80 Phase IInfectious-ViralOther Infectious-ViralSyntheticsSmall MoleculeLHF-535PRLink5 year, $5.8M grant
90
07/2019LyndraGileadOral drug delivery capsule technology to develop ultra-long-acting HIV therapiesLicenseFormulationInfectious-ViralHuman Immunodeficiency Virus/HIVDrug DeliveryOral, Sustained ReleasePRLink
91
07/2019NovartisGileadThree preclinical antiviral programs for rhinovirus, influenza and herpesLicensePreclinicalInfectious-ViralInfluenza, Other Infectious-ViralSyntheticsSmall MoleculePRLink$291M in development and commercial milestones
92
07/2019PhotocureAsierisCevira photodynamic drug-device combination to treat high-grade cervical dysplasiaLicensePhase IICancer, Infectious-ViralCervical, Other Infectious-ViralPhototherapyPRLink
93
06/2019AbCelleraGileadSingle-cell screening technology to generate antibody candidates for infectious diseasesLicense, ResearchDiscoveryInfectious-Bacterial, Infectious-ViralMonoclonals, ScreeningPRLink
94
06/2019Inovio PharmaceuticalsUS Dept of DefenseCELLECTRA 3PSP intradermal device for delivery of vaccines and immunotherapiesDevelopment 8.14 DeviceInfectious-Miscellaneous, Infectious-ViralDevice, VaccinesPRLink
95
05/2019Ichor BiologicsNIH$300K grant to develop broadly neutralizing antibodies against hantavirus infectionsDevelopment 0.30 Infectious-ViralOther Infectious-ViralMonoclonalsHuman AbsPRLink
96
05/2019NovanLigandAcquisition of milestone and royalty rights related to SB206 for molluscumAsset Purchase 12.00 Phase IIIDermatologic, Infectious-ViralOther Dermatologic, Other Infectious-ViralDrug Delivery, SyntheticsSmall Molecule, TopicalSEC RedactedLink 12.00 12.00 Ligand pays $12M and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones.
97
05/2019QiagenInovio PharmaceuticalsCompanion diagnostic for use with VGX-3100 immunotherapy for cervical dysplasia caused by HPVCo-Development, LicenseDiagnosticCancer, Infectious-ViralCervical, Other Infectious-ViralDiagnosticsVGX-3100E6 transforming protein, E7 transforming proteinPRLink
98
04/2019MedigeneAresus PharmaAcquisition of non-US rights to Veregen for genital wartsAsset PurchaseApprovedDermatologic, Infectious-ViralOther Dermatologic, Other Infectious-ViralDrug Delivery, SyntheticsSmall Molecule, TopicalVeregen, sinecatechins, kunecatechins, SB03, polyphenon eunknownPRLink
99
04/2019Samsung BiologicsCytoDynManufacturing of leronlimab (PRO 140)SupplyPhase IIICancer, Infectious-Viral, TransplantationBreast, Colorectal, Graft-versus-Host Disease, Human Immunodeficiency Virus/HIV, ProstateMonoclonalsHumanized Absleronlimab, PRO 140, PA-14, WHO 10751anti-CCR5 humanized IgG4 monoclonal antibody inhibitorCC chemokine receptor type 5 (CCR5) (CD195)SEC RedactedLink
100
03/2019AbCelleraBill & Melinda Gates FoundationRepertoire profiling to accelerate development of vaccines and antibody-based treatmentsResearch 4.80 Infectious-Bacterial, Infectious-Miscellaneous, Infectious-ViralHuman Immunodeficiency Virus/HIV, Malaria, TuberculosisPRLink